Clinical Trial Update: Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating anti-BCMA CAR-T cells for relapsed or refractory multiple myeloma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-BCMA CAR-T cells

Snippet

Sponsor: Thomas Martin, MD | Conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING